• Alias: XL-184
    • Potent inhibitor of RTKs, including AXL, FLT-3, KIT, MET, RET, TIE-2, TRKB, and VEGFR-1, -2, and -3
    • FDA approved in 2013 for MTC
    • Dose: 140 mg twice daily without food
    • Half-life: â™55 hours
    • Metabolism: Potent CYP3A4 substrate
    • Common side effects: Hemorrhage, perforation/fistula (US box warning), hypertension, stomatitis, palmar–plantar erythrodysesthesia, decreased appetite, weight loss, nausea/vomiting, diarrhea, tiredness and weakness, change in hair color, liver dysfunction (hyperbilirubinemia, transaminitis), dysphonia (hoarseness)
    • Clinical pearls: May affect the rate of wound healing; patients should notify doctor prior to surgery or dental work
    Other topics in Targeted and Immunotherapy Agents